Thyroid Disease in Perimenopause

Fatigue. Weight gain. Brain fog. Mood changes. Poor sleep. Hair thinning. Feeling cold. These symptoms appear on every perimenopause list. They also appear on every list of symptoms for hypothyroidism, an underactive thyroid. The overlap is nearly complete, and it creates a diagnostic problem: the right diagnosis is missed while the treatable cause goes unaddressed.

Hypothyroidism is common, its prevalence increases with age, and it is straightforwardly treatable; both conditions can be present simultaneously in midlife women. Getting the right assessment tells you what you are dealing with and opens the correct treatment path.

How Common Is Thyroid Disease in Midlife Women?

Thyroid disorders are approximately five to eight times more common in women than men, and prevalence increases with age.[1] The most common form is Hashimoto's thyroiditis, an autoimmune condition in which the immune system attacks the thyroid gland. Hashimoto's often develops or accelerates during periods of hormonal change, including perimenopause.

Data from the Colorado Thyroid Disease Prevalence Study found that 9.5% of women had elevated TSH (indicating subclinical or overt hypothyroidism), with prevalence rising after age 45.[2] In postmenopausal women, prevalence of subclinical hypothyroidism reaches approximately 20% in some studies, though many of these cases are mild and may not require treatment.[3]

The two conditions do not exclude each other.

Symptoms That Overlap Almost Completely

The symptoms at the bottom of this table help most with distinction. Vasomotor symptoms (hot flashes, night sweats) are characteristic of estrogen decline, not thyroid dysfunction. Vaginal dryness and genitourinary symptoms are driven by estrogen loss and do not occur in thyroid disease. Cold intolerance and constipation are more characteristic of hypothyroidism.

In the large overlap zone, symptoms alone cannot distinguish the two. A blood test is required.

What Tests to Request

TSH (thyroid-stimulating hormone) is the primary screening test. TSH is produced by the pituitary gland and regulates thyroid hormone output. When the thyroid is underproducing, TSH rises as the pituitary drives the thyroid harder. When the thyroid is overproducing, TSH falls.

A TSH within the normal reference range (typically 0.4–4.0 mIU/L, though ranges vary by laboratory) makes thyroid dysfunction an unlikely cause of symptoms. An elevated TSH warrants further investigation.

Free T4 (thyroxine) is the main hormone produced by the thyroid. If TSH is elevated, measuring free T4 determines whether the thyroid is compensating adequately (subclinical hypothyroidism: elevated TSH, normal T4) or failing (overt hypothyroidism: elevated TSH, low T4).

TPO antibodies (thyroid peroxidase antibodies) detect the autoimmune component. Elevated TPO antibodies indicate Hashimoto's thyroiditis, even if TSH and T4 are currently normal. Women with Hashimoto's progress to overt hypothyroidism at approximately 2–4% per year, a figure derived from the community-based Whickham Survey cohort tracking elevated TPO antibodies rather than a Hashimoto's-diagnosis population.[4]

Free T3 is sometimes measured in women with persistent symptoms despite normal TSH and T4. Some women convert T4 to the active form T3 less efficiently, producing hypothyroid-like symptoms with a normal T4. This is not universally agreed as a diagnostic entity within mainstream guidelines, but it is a reasonable test to request when standard results are normal and symptoms persist.

The Subclinical Zone

Subclinical hypothyroidism (elevated TSH with normal free T4) is common (approximately 4–10% of adults) and frequently asymptomatic.[5] Whether to treat it is debated.

NICE guidelines (2019) recommend considering a levothyroxine trial if TSH is above 10 mIU/L, or if TSH is between 4–10 in someone with symptoms consistent with hypothyroidism, under 65, and with positive TPO antibodies.[6]

For a perimenopausal woman with a TSH of, say, 6.5 and symptoms that overlap with perimenopause, a six-month trial of low-dose levothyroxine is a reasonable clinical approach. If symptoms improve with TSH normalisation, the thyroid was contributing. If they persist unchanged, perimenopause is the more dominant driver. This requires a GP or endocrinologist interpreting the result in the context of the full clinical picture.

How Estrogen Affects Thyroid Function

Estrogen increases thyroid-binding globulin (TBG), a protein that binds thyroid hormones in the bloodstream and reduces the amount of free, active hormone available.[7] This effect is more pronounced with oral estrogen (which raises TBG substantially) than with transdermal estrogen, which has minimal effect on TBG.

For women on oral HRT who have pre-existing hypothyroidism and are already taking levothyroxine, starting oral estrogen may reduce the effectiveness of their thyroid medication. Transdermal estrogen avoids this interaction. Women on levothyroxine who start oral HRT should have their TSH rechecked approximately six weeks after initiation.

When Both Are Present

Both perimenopause and hypothyroidism can coexist, with both contributing to symptoms. In this situation, treating thyroid dysfunction first (since it has a clear and reliable treatment) and reassessing after three to six months is a sensible approach. Residual symptoms after TSH normalisation can then be attributed to perimenopause and addressed accordingly.

If you are in midlife and experiencing fatigue, weight change, or mood and cognitive symptoms, you can proactively request a TSH test from your GP; you do not need to wait for it to be initiated. TSH testing is inexpensive, available through NHS primary care without specialist referral, and should be part of the workup for any woman in this age group with these symptoms. It does not replace perimenopause assessment, but it ensures the treatable cause is not missed.

References

[1] Vanderpump, M. P. (2011). The epidemiology of thyroid disease. British Medical Bulletin, 99(1), 39–51. https://doi.org/10.1093/bmb/ldr030

[2] Canaris, G. J., Manowitz, N. R., Mayor, G., Ridgway, E. C. (2000). The Colorado thyroid disease prevalence study. Archives of Internal Medicine, 160(4), 526–534. https://doi.org/10.1001/archinte.160.4.526

[3] Bjoro, T., Holmen, J., Kruger, O., et al. (2000). Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. European Journal of Endocrinology, 143(5), 639–647. https://doi.org/10.1530/eje.0.1430639

[4] Vanderpump, M. P., Tunbridge, W. M., French, J. M., et al. (1995). The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clinical Endocrinology, 43(1), 55–68. https://doi.org/10.1111/j.1365-2265.1995.tb01894.x

[5] Garber, J. R., Cobin, R. H., Gharib, H., et al. (2012). Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocrine Practice, 18(6), 988–1028. https://doi.org/10.4158/EP12280.GL

[6] National Institute for Health and Care Excellence. (2019). Thyroid disease: Assessment and management (NICE guideline NG145). NICE. https://www.nice.org.uk/guidance/ng145

[7] Arafah, B. M. (2001). Increased need for thyroxine in women with hypothyroidism during estrogen therapy. New England Journal of Medicine, 344(23), 1743–1749. https://doi.org/10.1056/NEJM200106073442302